Encequidar mesylate/Irinotecan

N/A

Report date: 2024/07/09 20:00:06

Base Information

Drug NameEncequidar mesylate/Irinotecan
Drug Alias NameHM-30181A+IrinotecanIrinotecan+HM30181AK-USIrinotecan+HM-30181AIrinotecan+HM30181AKIrinotecan/HM-30181A +[11] 
ClassificationSmall molecules
Mechanisms of ActionDNA topoisomerase I inhibitorsP-glycoprotein 1 inhibitors
TargetsP-glycoprotein 1DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsYes Encequidar mesylateIrinotecan hydrochloride
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAthenex IncMw Encap LtdAthenex Pharma Solutions Llc +[5] 
Inactive CompaniesHanmi Pharmaceutical Co Ltd
Active IndicationsBreast Neoplasms
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A